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OBJECTIVES: A vaccine to prevent infection with human papil-
lomavirus (HPV) types 6, 11, 16 and 18 may soon become avail-
able. The current strategy to prevent cervical cancer in the UK
is screening every 3 years, beginning at age 25 and then every 5
years for women aged 50+. The current screening coverage rate
is 81.2%. The objectives are to assess the health and economic
impact of HPV vaccination in association with current screening
in the UK compared to screening alone. METHODS: A Markov
model of the natural history of HPV infection incorporating
screening and vaccination was developed for the UK. A vaccine
that would prevent 90% of HPV 6, 11, 16 and 18-associated
disease, with 20 years duration and 87% coverage, given to girls
at age 12 in conjunction with current screening was compared
to screening alone using cost per life-year (LY) and quality-
adjusted life-year (QALY). Sensitivity analyses included varying
the vaccination cost from £165 to £220 and assuming a lifetime
duration for vaccine efﬁcacy. RESULTS: The model predicts the
reduction in lifetime risk of cervical cancer attributable to screen-
ing in line with already published UK data. Introduction of vac-
cination, and maintaining the screening programme unchanged,
would be expected to reduce the lifetime risk to 0.66%. Vacci-
nation with current screening is associated with an incremental
cost-effectiveness ratio (ICER) that varies from £16,000/QALY
(£20,600/LY) to £22,000/QALY (£28,200/LY) compared to
screening alone, when the vaccination cost is varied from £165
to £220. If a lifetime duration of vaccine efﬁcacy is assumed, the
ranges for the ICERs decrease to £12,750/QALY (£16,250/LY)
and £17,570/QALY (£22,400/LY) respectively. CONCLUSION:
These analyses suggest that adding a quadrivalent HPV vaccine
to current screening in the UK may be a cost-effective method
for further reducing the burden of cervical cancer.
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OBJECTIVE: Increasing antibiotic resistant staphylococcus
aureus strains in hospital- and chronic disease patients causing
a high burden of illness and consume enormous health care
resources in Germany. A new vaccine (StapVax) preventing
S.aureus infections is in clinical development and currently
seeking market authorization in the EU. The objective of this
analysis is to project the potential economic value of vaccinat-
ing hemodialysis patients with StapVax against mecillin resistant
staphylococcus aureus infections. METHODS: A literature-
based decision analysis model was developed to assess the annual
number of potential infections and death avoided as well as to
calculate cost-effectiveness, break-even price and budget impact
of the candidate vaccine. Baseline efﬁcacy rate was assumed to
be 57% with a 90% coverage rate. The model compared pro-
jected cost per infection avoided and cost per life-year gained for
patients receiving the vaccine versus unvaccinated patients
undergoing hemodialysis. RESULTS: Vaccinating the about
60,000 hemodialysis patients in Germany could prevent 650
S.aureus infections and 105 associated deaths per year. Assum-
ing annual per patient vaccination cost of €500 (vaccine plus
administration) the cost per infection avoided was estimated at
€27,000, with a cost per life-year gained of €17,000, respectively.
The net-budget impact in this scenario results in about €18
million. Vaccination cost of €170 would make the vaccine a
budget neutral preventive strategy. Monte Carlo simulations on
vaccine efﬁcacy, mortality rate after S.aureus infection, treatment
and vaccination cost resulted in cost per life-year gained ranging
from €3000 to €22,000 in 95% of the runs, and from €7000 to
€14,000 in 50% of trial runs. The model is most sensitive to
vaccine program cost and predicted preventive efﬁcacy. CON-
CLUSION: Vaccinating hemodialysis patients with StaphVax is
a highly cost-effective measure to prevent serious morbidity and
mortality in this patient population at substantial risk of bacte-
rial contamination.
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OBJECTIVES: To estimate the pharmacoeconomic impact of
preventing recurrent upper respiratory tract infections (URTIs)
with OM-85, a non-speciﬁc immunostimulating agent, in at-risk
children. METHODS: Implementation of a decisional model.
The evaluation of effectiveness (number of prevented
URTIs/therapeutic cycle) was based on weighted average of the
results of four randomized, double-blind, placebo-controlled
trials identiﬁed by literature reviewing. The clinical events con-
sidered in the model were natural resolution of the infection,
onset of complications (acute otitis media, sinusitis, others) and
their evolution. Baseline event probabilities were derived by
reviewing published data in the literature. URTI-related direct
and indirect costs supported by patients, by Italian health system
and by community were structured according with the principal
guidelines and implemented with current Italian prices and
tariffs. The cost-effectiveness of OM-85 was calculated for ﬁve
scenarios, differing in the number of therapeutic cycles, grade of
patient co-payment and other secondary assumptions. Sensibil-
ity analyses were performed to evaluate the model robustness.
RESULTS: Immunostimulation with one cycle of OM-85 pre-
vented on average 1.60 URTI/patient in 6 months (RR = 0.515).
In the basic scenario, this preventive action induced savings for
€107.42/patient in the perspective of the patient’s family, for
€48.52/patient in the perspective of Italian health system and for
231.26 in the community perspective. Sensibility analyses con-
ﬁrmed the robustness of basic scenario results. Threshold analy-
ses showed that OM-85 prophylaxis is economically convenient
as long as more than 7% of infections are prevented or global
cost of one episode of URTI is greater than €10.00. CONCLU-
SIONS: Non-speciﬁc immunotherapy with OM-85 induces a
reduction in the incidence of URTIs in at-risk children with a
concurrent saving for patients and health system.
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